Immunoglobulin E, complement, and eosinophils play an important role in host defense, but dysfunction of each of these components can lead to a variety of human disorders. In this review, we summarize how investigators have adapted gene therapy and antisense technology to modulate immunoglobulin E, complement, and/or eosinophil levels to treat these disorders.
BurtonOT, OettgenHC. Beyond immediate hypersensitivity: Evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol Rev, 2011; 242(1):128–143; doi: 10.1111/j.1600-065X.2011.01024.x
3.
KellyBT, GraysonMH. Immunoglobulin E, what is it good for?. Ann Allergy Asthma Immunol, 2016; 116(3):183–187; doi: 10.1016/j.anai.2015.10.026
4.
CapronM, CapronA. Immunoglobulin E and effector cells in schistosomiasis. Science, 1994; 264(5167):1876–1877; doi: 10.1126/science.8009216
5.
DunkelbergerJR, SongWC. Complement and its role in innate and adaptive immune responses. Cell Res, 2010; 20(1):34–50; doi: 10.1038/cr.2009.139
6.
CedzyńskiM, ThielensNM, MollnesTE, et al.Editorial: The role of complement in health and disease. Front Immunol, 2019; 10:1869; doi: 10.3389/fimmu.2019.01869
7.
JanewayCAJ, TraversP, WalportM, et al.Immunobiology: The Immune System in Health and Disease. Garland Science: New York; 2001.
8.
WechslerME, MunitzA, AckermanSJ, et al.Eosinophils in health and disease: A state-of-the-art review. Mayo Clin Proc, 2021; 96(10):2694–2707; doi: 10.1016/j.mayocp.2021.04.025
9.
SmithP, OwnbyDR. Clinical Significance of IgE. In: Middleton's Allergy: Principles and Practice, 7th ed. (Adkinson N, Bochner BS, Busse WW, et al. eds.) Mosby Elsevier: St Louis; 2009.
10.
VercelliD.Immunobiology of IgE In: Middleton's Allergy: Principles and Practice, 7th ed. (Adkinson N, Bochner BS, Busse WW, et al. eds.) Mosby Elsevier: St Louis; 2009.
11.
OettgenHC. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol, 2016; 137(6):1631–1645; doi: 10.1016/j.jaci.2016.04.009
12.
MerleNS, ChurchSE, Fremeaux-BacchiV, et al.Complement system part I—Molecular mechanisms of activation and regulation. Front Immunol, 2015; 6:262; doi: 10.3389/fimmu.2015.00262
13.
ReisES, MastellosDC, HajishengallisG, et al.New insights into the immune functions of complement. Nat Rev Immunol, 2019; 19(8):503–516; doi: 10.1038/s41577-019-0168-x
AckermanSJ, BochnerBS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am, 2007; 27(3):357–375; doi: 10.1016/j.iac.2007.07.004
JacksonDJ, AkuthotaP, RoufosseF. Eosinophils and eosinophilic immune dysfunction in health and disease. Eur Respir Rev, 2022; 31:163; doi: 10.1183/16000617.0150-2021
18.
BoyceJA, Assa'adA, BurksAW, et al.Guidelines for the diagnosis and management of food allergy in the United States: Report of the NIAID-sponsored expert panel. J Allergy Clin Immunol, 2010; 126(6Suppl):S1–S58.
OsborneNJ, KoplinJJ, MartinPE, et al.Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol, 2011; 127(3):668–676.e1–e2; doi: 10.1016/j.jaci.2011.01.039
21.
LyonsSA, ClausenM, KnulstAC, et al.Prevalence of food sensitization and food allergy in children across Europe. J Allergy Clin Immunol Pract, 2020; 8(8):2736–2746.e9; doi: 10.1016/j.jaip.2020.04.020
22.
GuptaRS, WarrenCM, SmithBM, et al.Prevalence and severity of food allergies among US adults. JAMA Netw Open, 2019; 2(1):e185630; doi: 10.1001/jamanetworkopen.2018.5630
23.
PateMB, SmithJK, ChiDS, et al.Regulation and dysregulation of immunoglobulin E: A molecular and clinical perspective. Clin Mol Allergy, 2010; 8:3.
24.
WuLC, ZarrinAA. The production and regulation of IgE by the immune system. Nat Rev Immunol, 2014; 14(4):247–259.
25.
GalliSJ, TsaiM. IgE and mast cells in allergic disease. Nat Med, 2012; 18(5):693–704; doi: 10.1038/nm.2755
26.
ShakerMS, WallaceDV, GoldenDBK, et al.Anaphylaxis—A 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol, 2020; 145(4):1082–1123; doi: 10.1016/j.jaci.2020.01.017
27.
GuptaRS, WarrenCM, SmithBM, et al.The public health impact of parent-reported childhood food allergies in the United States. Pediatrics, 2018; 142(6):e20183835; doi: 10.1542/peds.2018-1235-3835
28.
WarrenCM, ChadhaAS, SichererSH, et al.Prevalence and severity of sesame allergy in the United States. JAMA Netw Open, 2019; 2(8):e199144; doi: 10.1001/jamanetworkopen.2019.9144
29.
SampsonHA, AcevesS, BockSA, et al.Food allergy: A practice parameter update-2014. J Allergy Clin Immunol, 2014; 134(5):1016–1025.e43; doi: 10.1016/j.jaci.2014.05.013
30.
HerbertL, ShemeshE, BenderB. Clinical management of psychosocial concerns related to food allergy. J Allergy Clin Immunol Pract, 2016; 4(2):205–213; doi: 10.1016/j.jaip.2015.10.016
31.
JonesCJ, LlewellynCD, FrewAJ, et al.Factors associated with good adherence to self-care behaviours amongst adolescents with food allergy. Pediatr Allergy Immunol, 2015; 26(2):111–118; doi: 10.1111/pai.12333
32.
LicariA, MantiS, MarsegliaA, et al.Food allergies: Current and future treatments. Medicina (Kaunas), 2019; 55(5):120; doi: 10.3390/medicina55050120
33.
GreenhawtM, ShakerM, WangJ, et al.Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis. J Allergy Clin Immunol, 2020; 146(6):1302–1334; doi: 10.1016/j.jaci.2020.07.031
34.
de SilvaD, Rodríguez del RíoP, de JongNW, et al.Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy, 2022; 77(6):1852–1862; doi: doi.org/10.1111/all.15211
35.
RoyK, MaoHQ, HuangSK, et al.Oral gene delivery with chitosan—DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med, 1999; 5(4):387–391.
36.
PagovichOE, WangB, ChiuchioloMJ, et al.Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. J Allergy Clin Immunol, 2016; 138(6):1652–1662; doi: S0091-6749(16)30286-X[pii];10.1016/j.jaci.2016.03.053[doi]
37.
WinterWE, HardtNS, FuhrmanS. Immunoglobulin E: Importance in parasitic infections and hypersensitivity responses. Arch Pathol Lab Med, 2000; 124(9):1382–1385.
38.
CooperPJ, AyreG, MartinC, et al.Geohelminth infections: A review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy, 2008; 63(4):409–417.
39.
KimHL, LeighR, BeckerA. Omalizumab: Practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol, 2010; 6(1):32.
40.
AliAK, HartzemaAG. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy, 2012; 5:1–9.
41.
BusseW, BuhlR, FernandezVC, et al.Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol, 2012; 129(4):983–989.
42.
LongA, RahmaouiA, RothmanKJ, et al.Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol, 2014; 134(3):560–567.
43.
MagenE, SchlesingerM, DavidM, et al.Selective IgE deficiency, immune dysregulation, and autoimmunity. Allergy Asthma Proc, 2014; 35(2):e27–e33.
44.
LaiT, WangS, XuZ, et al.Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis. Sci Rep, 2015; 5:8191.
BosseY, ParePD, SeowCY. Airway wall remodeling in asthma: From the epithelial layer to the adventitia. Curr Allergy Asthma Rep, 2008; 8(4):357–366.
48.
BusseWW, KraftM, RabeKF, et al.Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J, 2021; 58(2):2003393; doi: 10.1183/13993003.03393-2020
49.
BurrowsB, MartinezFD, HalonenM, et al.Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med, 1989; 320(5):271–277; doi: 10.1056/nejm198902023200502
50.
HoltPG, MacaubasC, StumblesPA, et al.The role of allergy in the development of asthma. Nature, 1999; 402(6760 Suppl):B12–B17; doi: 10.1038/35037009
51.
KayAB. Allergy and allergic diseases. Second of two parts. N Engl J Med, 2001; 344(2):109–113; doi: 10.1056/nejm200101113440206
Platts-MillsTA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med, 2001; 164(8 Pt 2):S1–S5; doi: 10.1164/ajrccm.164.supplement_1.2103024
55.
AminK. The role of mast cells in allergic inflammation. Respir Med, 2012; 106(1):9–14; doi: 10.1016/j.rmed.2011.09.007
56.
McGeeHS, AgrawalDK. TH2 cells in the pathogenesis of airway remodeling: Regulatory T cells a plausible panacea for asthma. Immunol Res, 2006; 35(3):219–232; doi: 10.1385/ir:35:3:219
57.
HillasG, FoukaE, PapaioannouAI. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: A review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med, 2020; 14(4):353–365; doi: 10.1080/17476348.2020.1718495
58.
WenzelS, FordL, PearlmanD, et al.Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med, 2013; 368(26):2455–2466; doi: 10.1056/NEJMoa1304048
59.
CastroM, CorrenJ, PavordID, et al.Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med, 2018; 378(26):2486–2496; doi: 10.1056/NEJMoa1804092
60.
RabeKF, NairP, BrusselleG, et al.Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med, 2018; 378(26):2475–2485; doi: 10.1056/NEJMoa1804093
61.
WalshGM. Anti-IL-5 monoclonal antibodies for the treatment of asthma: An update. Expert Opin Biol Ther, 2020; 20(10):1237–1244; doi: 10.1080/14712598.2020.1782381
62.
BacharierLB, MasperoJF, KatelarisCH, et al.Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med, 2021; 385(24):2230–2240; doi: 10.1056/NEJMoa2106567
63.
PrincipeS, PorsbjergC, Bolm DitlevS, et al.Treating severe asthma: Targeting the IL-5 pathway. Clin Exp Allergy, 2021; 51(8):992–1005; doi: 10.1111/cea.13885
64.
HolgateS, CasaleT, WenzelS, et al.The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol, 2005; 115(3):459–465; doi: 10.1016/j.jaci.2004.11.053
65.
BusseWW, MorganWJ, GergenPJ, et al.Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med, 2011; 364(11):1005–1015; doi: 10.1056/NEJMoa1009705
66.
DurrantDM, MetzgerDW. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest, 2010; 39(4–5):526–549; doi: 10.3109/08820131003615498
67.
LiXM, ChopraRK, ChouTY, et al.Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice. J Immunol, 1996; 157(8):3216–3219.
68.
DowSW, SchwarzeJ, HeathTD, et al.Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum Gene Ther, 1999; 10(12):1905–1914; doi: 10.1089/10430349950017266
69.
KongX, HellermannGR, ZhangW, et al.Chitosan interferon-gamma nanogene therapy for lung disease: Modulation of T-cell and dendritic cell immune responses. Allergy Asthma Clin Immunol, 2008; 4(3):95–105; doi: 10.1186/1710-1492-4-3-95
70.
TakatsuK. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci, 2011; 87(8):463–485; doi: 10.2183/pjab.87.463
71.
HuangHY, LeeCC, ChiangBL. Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness. Gene Ther, 2008; 15(9):660–667; doi: 10.1038/gt.2008.15
72.
CaoY, ZengD, SongQ, et al.The effects of antisense interleukin-4 gene transferred by recombinant adeno-associated virus vector on the airway remodeling in allergic rats. J Asthma, 2010; 47(9):951–958; doi: 10.1080/02770903.2010.514635
73.
ZengD, CaoY, SongQ, et al.Effects of antisense interleukin-5 gene transferred by recombinant adeno-associated virus to allergic rats. Respirology, 2010; 15(1):132–140; doi: 10.1111/j.1440-1843.2009.01670.x
74.
ZengD, CaoY, SongQ, et al.Recombinant adeno-associated virus vector-mediated delivery of antisense interleukin-5 gene attenuates airway remodeling in allergic rats. Int Arch Allergy Immunol, 2011; 154(3):207–215; doi: 10.1159/000321107
75.
FuCL, YeYL, LeeYL, et al.Effects of overexpression of IL-10, IL-12, TGF-beta and IL-4 on allergen induced change in bronchial responsiveness. Respir Res, 2006; 7:72; doi: 10.1186/1465-9921-7-72
76.
LiH, XieQ, WangH, et al.Intramuscular delivery of mIL-12 gene reduces the expression of CD44/CD49d on pulmonary leucocytes and inhibits ovalbumin-induced airway hyperreactivity. Inflamm Res, 2008; 57(1):11–17; doi: 10.1007/s00011-007-7042-1
77.
HsuCY, LiuHE, SheuFY, et al.Synergistic therapeutic effects of combined adenovirus-mediated interleukin-10 and interleukin-12 gene therapy on airway inflammation in asthmatic mice. J Gene Med, 2010; 12(1):11–21; doi: 10.1002/jgm.1408
78.
LeeYL, YeYL, YuCI, et al.Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum Gene Ther, 2001; 12(17):2065–2079; doi: 10.1089/10430340152677412
79.
HoganSP, FosterPS, TanX, et al.Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol, 1998; 28(2):413–423; doi: 10.1002/(sici)1521-4141(199802)28:02<413::Aid-immu413>3.0.Co;2-1
80.
WalterDM, McIntireJJ, BerryG, et al.Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol, 2001; 167(8):4668–4675; doi: 10.4049/jimmunol.167.8.4668
81.
ZavorotinskayaT, TomkinsonA, MurphyJE. Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13. Mol Ther, 2003; 7(2):155–162.
82.
KarrasJG, CrosbyJR, GuhaM, et al.Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol, 2007; 36(3):276–285; doi: 10.1165/rcmb.2005-0456OC
83.
WangG, LuJ. Retrovirus-mediated delivery of an IL-4 receptor antagonist inhibits allergic responses in a murine model of asthma. Sci China Life Sci, 2010; 53(10):1215–1220; doi: 10.1007/s11427-010-4067-4
84.
HansenG, McIntireJJ, YeungVP, et al.CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest, 2000; 105(1):61–70; doi: 10.1172/jci7589
85.
DinarelloCA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 2011; 117(14):3720–3732; doi: 10.1182/blood-2010-07-273417
86.
WangCC, FuCL, YangYH, et al.Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther, 2006; 13(19):1414–1421; doi: 10.1038/sj.gt.3302798
87.
WangSY, YangM, XuXP, et al.Intranasal delivery of T-bet modulates the profile of helper T cell immune responses in experimental asthma. J Investig Allergol Clin Immunol, 2008; 18(5):357–365.
88.
LopezE, del PozoV, MiguelT, et al.Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J Immunol, 2006; 176(3):1943–1950.
89.
del PozoV, RojoM, RubioML, et al.Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation. Am J Respir Crit Care Med, 2002; 166(5):732–737; doi: 10.1164/rccm.2111031
90.
ZhangDH, YangL, CohnL, et al.Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity, 1999; 11(4):473–482; doi: 10.1016/s1074-7613(00)80122-3
91.
FinottoS, De SanctisGT, LehrHA, et al.Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med, 2001; 193(11):1247–1260.
SelS, WegmannM, DickeT, et al.Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol, 2008; 121(4):910–916.e5; doi: 10.1016/j.jaci.2007.12.1175
94.
AnoS, MorishimaY, IshiiY, et al.Transcription factors GATA-3 and RORγt are important for determining the phenotype of allergic airway inflammation in a murine model of asthma. J Immunol, 2013; 190(3):1056–1065; doi: 10.4049/jimmunol.1202386
95.
HoylerT, KloseCS, SouabniA, et al.The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity, 2012; 37(4):634–648; doi: 10.1016/j.immuni.2012.06.020
96.
MjösbergJ, BerninkJ, GolebskiK, et al.The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity, 2012; 37(4):649–659; doi: 10.1016/j.immuni.2012.08.015
97.
KiwamotoT, IshiiY, MorishimaY, et al.Transcription factors T-bet and GATA-3 regulate development of airway remodeling. Am J Respir Crit Care Med, 2006; 174(2):142–151; doi: 10.1164/rccm.200601-079OC
98.
DesmetC, GossetP, PajakB, et al.Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol, 2004; 173(9):5766–5775; doi: 10.4049/jimmunol.173.9.5766
99.
QuarcooD, WeixlerS, GronebergD, et al.Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. J Allergy Clin Immunol, 2004; 114(2):288–295; doi: 10.1016/j.jaci.2004.03.055
100.
DesmetC, GossetP, HenryE, et al.Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. Am J Respir Crit Care Med, 2005; 172(6):671–678; doi: 10.1164/rccm.200410-1431OC
101.
LührmannA, TschernigT, von der LeyenH, et al.Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model. Exp Lung Res, 2010; 36(2):85–93; doi: 10.3109/01902140903144138
102.
HensonPM, TuderRM. Apoptosis in the lung: induction, clearance and detection. Am J Physiol Lung Cell Mol Physiol, 2008; 294(4):L601–L611; doi: 10.1152/ajplung.00320.2007
103.
PossaSS, LeickEA, PradoCM, et al.Eosinophilic inflammation in allergic asthma. Front Pharmacol, 2013; 4:46; doi: 10.3389/fphar.2013.00046
104.
ChuangYH, FuCL, LoYC, et al.Adenovirus expressing Fas ligand gene decreases airway hyper-responsiveness and eosinophilia in a murine model of asthma. Gene Ther, 2004; 11(20):1497–1505; doi: 10.1038/sj.gt.3302325
105.
ChuangYH, SuenJL, ChiangBL. Fas-ligand-expressing adenovirus-transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma. J Mol Med (Berl), 2006; 84(7):595–603; doi: 10.1007/s00109-006-0047-3
106.
da SilvaAL, MartiniSV, AbreuSC, et al.DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma. J Control Release, 2014; 180:125–133; doi: 10.1016/j.jconrel.2014.02.010
107.
StentonGR, UlanovaM, DeryRE, et al.Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol, 2002; 169(2):1028–1036.
108.
ChoiIW, KimDK, KoHM, et al.Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice. Int Immunopharmacol, 2004; 4(14):1817–1828; doi: 10.1016/j.intimp.2004.07.030
109.
YangCJ, LiuYK, LiuCL, et al.Inhibition of acidic mammalian chitinase by RNA interference suppresses ovalbumin-sensitized allergic asthma. Hum Gene Ther, 2009; 20(12):1597–1606; doi: 10.1089/hum.2008.092
110.
BarnesPJ. New therapies for asthma: Is there any progress?. Trends Pharmacol Sci, 2010; 31(7):335–343; doi: 10.1016/j.tips.2010.04.009
111.
LaiWQ, GohHH, BaoZ, et al.The role of sphingosine kinase in a murine model of allergic asthma. J Immunol, 2008; 180(6):4323–4329; doi: 10.4049/jimmunol.180.6.4323
112.
GauvreauGM, BouletLP, CockcroftDW, et al.Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med, 2008; 177(9):952–958; doi: 10.1164/rccm.200708-1251OC
113.
ImaokaH, CampbellH, BabiradI, et al.TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin Exp Allergy, 2011; 41(12):1740–1746; doi: 10.1111/j.1365-2222.2011.03816.x
114.
KrugN, HohlfeldJM, KirstenAM, et al.Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med, 2015; 372(21):1987–1995; doi: 10.1056/NEJMoa1411776
115.
BousquetJ, KhaltaevN, CruzAA, et al.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy, 2008; 63(Suppl 86):8–160; doi: 10.1111/j.1398-9995.2007.01620.x
DykewiczMS, WallaceDV, AmrolDJ, et al.Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol, 2020; 146(4):721–767; doi: 10.1016/j.jaci.2020.07.007
118.
SaloPM, ArbesSJJr., JaramilloR, et al.Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005–2006. J Allergy Clin Immunol, 2014; 134(2):350–359; doi: 10.1016/j.jaci.2013.12.1071
119.
ArbesSJJr., GergenPJ, ElliottL, et al.Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol, 2005; 116(2):377–383; doi: 10.1016/j.jaci.2005.05.017
120.
MeltzerEO, BlaissMS, DereberyMJ, et al.Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey. J Allergy Clin Immunol, 2009; 124(3 Suppl):S43–S70; doi: 10.1016/j.jaci.2009.05.013
121.
GuerraS, SherrillDL, MartinezFD, et al.Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol, 2002; 109(3):419–425; doi: 10.1067/mai.2002.121701
122.
ShaabanR, ZureikM, SoussanD, et al.Rhinitis and onset of asthma: A longitudinal population-based study. Lancet, 2008; 372(9643):1049–1057; doi: 10.1016/s0140-6736(08)61446-4
123.
BieloryL. Allergic conjunctivitis and the impact of allergic rhinitis. Curr Allergy Asthma Rep, 2010; 10(2):122–134; doi: 10.1007/s11882-010-0087-1
124.
HopperJL, BuiQM, ErbasB, et al.Does eczema in infancy cause hay fever, asthma, or both in childhood? Insights from a novel regression model of sibling data. J Allergy Clin Immunol, 2012; 130(5):1117–1122.e1; doi: 10.1016/j.jaci.2012.08.003
125.
WagnerJG, HarkemaJR. Rodent models of allergic rhinitis: Relevance to human pathophysiology. Curr Allergy Asthma Rep, 2007; 7(2):134–140.
126.
BraidoF, ArcadipaneF, MarugoF, et al.Allergic rhinitis: Current options and future perspectives. Curr Opin Allergy Clin Immunol, 2014; 14(2):168–176; doi: 10.1097/ACI.0000000000000043
127.
MimsJW. Epidemiology of allergic rhinitis. Int Forum Allergy Rhinol, 2014; 4(Suppl 2):S18–S20; doi: 10.1002/alr.21385
128.
HolgateST, PolosaR. Treatment strategies for allergy and asthma. Nat Rev Immunol, 2008; 8(3):218–230; doi: 10.1038/nri2262
129.
ChatilaTA, LiN, Garcia-LloretM, et al.T-cell effector pathways in allergic diseases: Transcriptional mechanisms and therapeutic targets. J Allergy Clin Immunol, 2008; 121(4):812–823; quiz 824–825; doi: 10.1016/j.jaci.2008.02.025
130.
OhCK, GebaGP, MolfinoN. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev, 2010; 19(115):46–54; doi: 10.1183/09059180.00007609
131.
KupermanDA, HuangX, KothLL, et al.Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med, 2002; 8(8):885–889; doi: 10.1038/nm734
132.
Darcan-NicolaisenY, MeinickeH, FelsG, et al.Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. J Immunol, 2009; 182(12):7501–7508; doi: 10.4049/jimmunol.0713433
133.
WuH, SuZ, BarniePA. The role of B regulatory (B10) cells in inflammatory disorders and their potential as therapeutic targets. Int Immunopharmacol, 2020; 78:106111; doi: 10.1016/j.intimp.2019.106111
134.
ZhuXH, LiaoB, LiuK, et al.Effect of RNA interference therapy on the mice eosinophils CCR3 gene and granule protein in the murine model of allergic rhinitis. Asian Pac J Trop Med, 2014; 7(3):226–230; doi: 10.1016/S1995-7645(14)60026-2
135.
SuzukiM, ZhengX, ZhangX, et al.Inhibition of allergic responses by CD40 gene silencing. Allergy, 2009; 64(3):387–397; doi: 10.1111/j.1398-9995.2008.01839.x
136.
HeJ, WangT, YaoL, et al.Construction and delivery of gene therapy vector containing soluble TNFalpha receptor-IgGFc fusion gene for the treatment of allergic rhinitis. Cytokine, 2006; 36(5–6):296–304; doi: 10.1016/j.cyto.2007.02.010
137.
HanDM, ZhouB, WangT, et al.Intranasal application of Epstein-Barr virus/lipoplex to abrogate eosinophillia in murine model of allergic rhinitis. Chin Med J (Engl), 2006; 119(12):991–997.
138.
FlohrC, MannJ. New insights into the epidemiology of childhood atopic dermatitis. Allergy, 2014; 69(1):3–16; doi: 10.1111/all.12270
139.
SchneiderL, TillesS, LioP, et al.Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol, 2013; 131(2):295–299.e1–e27; doi: 10.1016/j.jaci.2012.12.672
140.
LeungDY. New insights into atopic dermatitis: Role of skin barrier and immune dysregulation. Allergol Int, 2013; 62(2):151–161; doi: 10.2332/allergolint.13-RAI-0564
TsuyukiS, TsuyukiJ, EinsleK, et al.Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. J Exp Med, 1997; 185(9):1671–1679; doi: 10.1084/jem.185.9.1671
143.
LarchéM, TillSJ, HaseldenBM, et al.Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J Immunol, 1998; 161(11):6375–6382.
144.
HaczkuA, TakedaK, RedaiI, et al.Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice. Am J Respir Crit Care Med, 1999; 159(5 Pt 1):1638–1643; doi: 10.1164/ajrccm.159.5.9711040
145.
NesargikarPN, SpillerB, ChavezR. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol, 2012; 2(2):103–111; doi: 10.1556/EuJMI.2.2012.2.2
146.
BottoM, KirschfinkM, MacorP, et al.Complement in human diseases: Lessons from complement deficiencies. Mol Immunol, 2009; 46(14):2774–2783; doi: 10.1016/j.molimm.2009.04.029
147.
Antwi-BaffourS, KyeremehR, AdjeiJK, et al.The relative merits of therapies being developed to tackle inappropriate (‘self’-directed) complement activation. Auto Immun Highlights, 2016; 7(1):6; doi: 10.1007/s13317-016-0078-x
148.
WenL, AtkinsonJP, GiclasPC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol, 2004; 113(4):585–593; quiz 594; doi: 10.1016/j.jaci.2004.02.003
149.
CarrollMV, SimRB. Complement in health and disease. Adv Drug Deliv Rev, 2011; 63(12):965–975; doi: 10.1016/j.addr.2011.06.005
150.
PickeringMC, BottoM, TaylorPR, et al.Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol, 2000; 76:227–324; doi: 10.1016/s0065-2776(01)76021-x
151.
JönssonG, TruedssonL, SturfeltG, et al.Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore), 2005; 84(1):23–34; doi: 10.1097/01.md.0000152371.22747.1e
152.
TruedssonL, AlperCA, AwdehZL, et al.Characterization of type I complement C2 deficiency MHC haplotypes. Strong conservation of the complotype/HLA-B-region and absence of disease association due to linked class II genes. J Immunol, 1993; 151(10):5856–5863.
153.
WetselRA, KulicsJ, LokkiML, et al.Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189—>Phe; Gly444—>Arg) cause impaired C2 secretion. J Biol Chem, 1996; 271(10):5824–5831; doi: 10.1074/jbc.271.10.5824
154.
RakheS, CardinalM, PatelN, et al.In vivo characterization of an AAV vector expressing complement component C2. Mol Ther, 2020; 28:358.
ZurawBL, BanerjiA, BernsteinJA, et al.US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract, 2013; 1(5):458–467; doi: 10.1016/j.jaip.2013.07.002
157.
LonghurstHJ, BorkK. Hereditary angioedema: An update on causes, manifestations and treatment. Br J Hosp Med (Lond), 2019; 80(7):391–398; doi: 10.12968/hmed.2019.80.7.391
158.
ZurawBL, ChristiansenSC. HAE Pathophysiology and Underlying Mechanisms. Clin Rev Allergy Immunol, 2016; 51(2):216–229; doi: 10.1007/s12016-016-8561-8
159.
WalfordHH, ZurawBL. Current update on cellular and molecular mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol, 2014; 112(5):413–418; doi: 10.1016/j.anai.2013.12.023
160.
ZurawBL. The pathophysiology of hereditary angioedema. World Allergy Organ J, 2010; 3(9 Suppl):S25–S28; doi: 10.1097/WOX.0b013e3181f3f21c
161.
NussbergerJ, CugnoM, CicardiM, et al.Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol, 1999; 104(6):1321–1322; doi: 10.1016/s0091-6749(99)70030-8
162.
CugnoM, NussbergerJ, CicardiM, et al.Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol, 2003; 3(3):311–317; doi: 10.1016/s1567-5769(02)00162-5
163.
KaplanAP, JosephK. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol, 2010; 104(3):193–204; doi: 10.1016/j.anai.2010.01.007
164.
QiuT, ChiuchioloMJ, WhaleyAS, et al.Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. Allergy, 2019; 74(6):1081–1089; doi: 10.1111/all.13582
165.
WoloszynekJ, SatheA, WebsterK, et al.AAV gene therapy to provide continuous C1-INH expression to treat hereditary angioedema. Mol Ther, 2020; 28:89.
166.
BanerjiA, BusseP, ShennakM, et al.Inhibiting plasma Kallikrein for hereditary angioedema prophylaxis. N Engl J Med, 2017; 376(8):717–728; doi: 10.1056/NEJMoa1605767
167.
LonghurstHJ, FijenLM, LindsayK, et al.In vivo CRISPR/Cas9 editing of KLKB1 in patients with hereditary angioedema: A first-in-human study; 2022. Available from: https://www.intelliatx.com/wp-content/uploads/In-vivo-CRISPR-CAS9-editing-of-KLKB1-in-patients-with-HAE_ACAAI_2022_Nov_12_vF.pdf [Last accessed: October4, 2023].
168.
BruderJT, XuW, McDougaldDS, et al.AAV-mediated antibody delivery for hereditary angioedema. Mol Ther, 2020; 28:94.
169.
GotlibJ. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol, 2015; 90(11):1077–1089; doi: 10.1002/ajh.24196
170.
RothenbergME, HoganSP. The eosinophil. Annu Rev Immunol, 2006; 24:147–174; doi: 10.1146/annurev.immunol.24.021605.090720
171.
BochnerBS. The eosinophil: For better or worse, in sickness and in health. Ann Allergy Asthma Immunol, 2018; 121(2):150–155; doi: 10.1016/j.anai.2018.02.031
172.
ParkYM, BochnerBS. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res, 2010; 2(2):87–101; doi: 10.4168/aair.2010.2.2.87
173.
PodjasekJC, ButterfieldJH. Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leuk Res, 2013; 37(4):392–395; doi: 10.1016/j.leukres.2012.12.016
174.
GotlibJ. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol, 2017; 92(11):1243–1259; doi: 10.1002/ajh.24880
DunphyCH. Chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Cancer Ther Rev, 2012; 8:30–34.
177.
PagovichOE, StilesKM, CamilleriAE, et al.Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS). Leukemia, 2022; 36(2):525–531; doi: 10.1038/s41375-021-01400-4
178.
CamilleriAE, NagS, RussoAR, et al.Gene therapy for a murine model of eosinophilic esophagitis. Allergy, 2021; 76(9):2740–2752; doi: 10.1111/all.14822
179.
TianD, FuZ, LiuE, et al.Therapeutic effect of intratracheal administration of murine IL-4 receptor antagonist on asthmatic airway inflammation. J Asthma, 2008; 45(8):715–721; doi: 10.1080/02770900802252085
CrosbyJR, GuhaM, TungD, et al.Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther, 2007; 321(3):938–946; doi: 10.1124/jpet.106.119214
182.
MaysLE, Ammon-TreiberS, MothesB, et al.Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. J Clin Invest, 2013; 123(3):1216–1228; doi: 10.1172/JCI65351
183.
SatoJ, KonnoN, MurakamiM, et al.Adenovirus-mediated ICOSIg gene therapy in a presensitized murine model of allergic rhinitis. Adv Otorhinolaryngol, 2016; 77:59–66; doi: 10.1159/000441876
184.
HosoyaK, SatohT, YamamotoY, et al.Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis. Allergy, 2011; 66(1):124–131; doi: 10.1111/j.1398-9995.2010.02440.x
185.
PagovichOE, NagS, CamilleriAE, et al.Gene therapy for chronic eosinophilic leukemia. Mol Ther, 2019; 27:166.
186.
PagovichOE, RussoAR, WhaleyAS, et al.Gene therapy for chronic eosinophilic esophagitis. Mol Ther, 2018; 26:161.
187.
PagovichOE, CamilleriAE, NagS, et al.AAV-mediated anti-eosinophil gene therapy for eosinophilic esophagitis. Mol Ther, 2020; 28:90.
